Global Dermatophytosis Drugs Market

Dermatophytosis Drugs Comprehensive Study by Application (Superficial Antifungal Infections, Systemic Antifungal Infections), Route of Administration (Oral, Topical, Parenteral), Form (Powder, Ointments, Tablets), End-Use (Adult, Kids) Players and Region - Global Market Outlook to 2028

Dermatophytosis Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Dermatophytosis drugs are used to identify and remove fungal infections with minimal side effects on the body. Unhygienic and unclean environments in which fungal agents grow cause fungal infection in the body. These agents replicate by disseminating spores, which then cause infections on the skin (superficial) or in the lungs (systemic)-fungal infections. Candidaiasis, fungal pneumonia, mucormycosis, and other diseases are caused by a fungal infection. These infections are usually non-lethal, but in extreme circumstances, they can be fatal.Since fungi can affect anyone, they are considered a public health concern. Fungal infections, on the other hand, pose a serious danger to people with weakened immune systems, such as AIDS patients. In these patients, there is a high risk of developing opportunistic fungal infections.

Highlights from Dermatophytosis Drugs Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The key Players profiled in the report are Abbott Laboratories (United States), Astellas Pharma Inc. (Japan), Bayer AG (Germany), GlaxoSmithKline PLC (United Kingdom), Glenmark Pharmaceuticals (India), Merck & Co. Inc. (United States), Novartis AG (Switzerland), Pfizer Inc. (United States), SCYNEXIS Inc. (United States) and Kramer Laboratories (United States).

Geographic Breakdown and Segment Analysis
The Global Dermatophytosis Drugs market presents a comprehensive analysis of the Dermatophytosis Drugs market by end-user/application (Superficial Antifungal Infections and Systemic Antifungal Infections), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Dermatophytosis Drugs industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the holds majority of market share of the Dermatophytosis Drugs market

Analyst at AMA have segmented the market study of Global Dermatophytosis Drugs market by Type, Application and Region.

Influencing Trend:
Rising Consumption of Anti-fungal Drugs in Developing Regions for a Variety of Medical Conditions

Market Growth Drivers:
Increasing prevalence of Fungal infection and Rising awareness levels pertaining to myriad fungal infections

Restraints:
Increasing Resistance to Antifungal Drugs and Side Effects of Antifungal Drugs

Opportunities:
Rising concern towards Health and Increasing support from Government and Non – Government organization

Market Developments Activities:
In November 2023, Astellas Pharma Inc. and Propella Therapeutics, Inc. announced that Astellas, through a US subsidiary, and Propella have entered into a merger agreement pursuant to which Astellas acquired Propella.
In October 2023, Abbott Laboratories the market was overestimating the hit to sales of its glucose monitoring products from growing popularity of new diabetes drugs, adding the treatments could end up boosting sales of the medical device maker.



The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail of competitive advantage through combined collaborations.

Key Target Audience
Manufacturers of Dermatophytosis Drugs, Suppliers of Dermatophytosis Drugs, Wholesalers, Distributors and Retailers of Dermatophytosis Drugs, Pharmaceutical Industry, Regulatory Bodies and Others

Report Objectives / Segmentation Covered

By Application
  • Superficial Antifungal Infections
  • Systemic Antifungal Infections
By Route of Administration
  • Oral
  • Topical
  • Parenteral

By Form
  • Powder
  • Ointments
  • Tablets

By End-Use
  • Adult
  • Kids

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence of Fungal infection
      • 3.2.2. Rising awareness levels pertaining to myriad fungal infections
    • 3.3. Market Trends
      • 3.3.1. Rising Consumption of Anti-fungal Drugs in Developing Regions for a Variety of Medical Conditions
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dermatophytosis Drugs, by Application, Route of Administration, Form, End-Use and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Dermatophytosis Drugs (Value)
      • 5.2.1. Global Dermatophytosis Drugs by: Application (Value)
        • 5.2.1.1. Superficial Antifungal Infections
        • 5.2.1.2. Systemic Antifungal Infections
      • 5.2.2. Global Dermatophytosis Drugs by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Topical
        • 5.2.2.3. Parenteral
      • 5.2.3. Global Dermatophytosis Drugs by: Form (Value)
        • 5.2.3.1. Powder
        • 5.2.3.2. Ointments
        • 5.2.3.3. Tablets
      • 5.2.4. Global Dermatophytosis Drugs by: End-Use (Value)
        • 5.2.4.1. Adult
        • 5.2.4.2. Kids
      • 5.2.5. Global Dermatophytosis Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Dermatophytosis Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Astellas Pharma Inc. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Glenmark Pharmaceuticals (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co. Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. SCYNEXIS Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Kramer Laboratories (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Dermatophytosis Drugs Sale, by Application, Route of Administration, Form, End-Use and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Dermatophytosis Drugs (Value)
      • 7.2.1. Global Dermatophytosis Drugs by: Application (Value)
        • 7.2.1.1. Superficial Antifungal Infections
        • 7.2.1.2. Systemic Antifungal Infections
      • 7.2.2. Global Dermatophytosis Drugs by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Topical
        • 7.2.2.3. Parenteral
      • 7.2.3. Global Dermatophytosis Drugs by: Form (Value)
        • 7.2.3.1. Powder
        • 7.2.3.2. Ointments
        • 7.2.3.3. Tablets
      • 7.2.4. Global Dermatophytosis Drugs by: End-Use (Value)
        • 7.2.4.1. Adult
        • 7.2.4.2. Kids
      • 7.2.5. Global Dermatophytosis Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dermatophytosis Drugs: by Application(USD Million)
  • Table 2. Dermatophytosis Drugs Superficial Antifungal Infections , by Region USD Million (2017-2022)
  • Table 3. Dermatophytosis Drugs Systemic Antifungal Infections , by Region USD Million (2017-2022)
  • Table 4. Dermatophytosis Drugs: by Route of Administration(USD Million)
  • Table 5. Dermatophytosis Drugs Oral , by Region USD Million (2017-2022)
  • Table 6. Dermatophytosis Drugs Topical , by Region USD Million (2017-2022)
  • Table 7. Dermatophytosis Drugs Parenteral , by Region USD Million (2017-2022)
  • Table 8. Dermatophytosis Drugs: by Form(USD Million)
  • Table 9. Dermatophytosis Drugs Powder , by Region USD Million (2017-2022)
  • Table 10. Dermatophytosis Drugs Ointments , by Region USD Million (2017-2022)
  • Table 11. Dermatophytosis Drugs Tablets , by Region USD Million (2017-2022)
  • Table 12. Dermatophytosis Drugs: by End-Use(USD Million)
  • Table 13. Dermatophytosis Drugs Adult , by Region USD Million (2017-2022)
  • Table 14. Dermatophytosis Drugs Kids , by Region USD Million (2017-2022)
  • Table 15. South America Dermatophytosis Drugs, by Country USD Million (2017-2022)
  • Table 16. South America Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 17. South America Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 18. South America Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 19. South America Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 20. Brazil Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 21. Brazil Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 22. Brazil Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 23. Brazil Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 24. Argentina Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 25. Argentina Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 26. Argentina Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 27. Argentina Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 28. Rest of South America Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 29. Rest of South America Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 30. Rest of South America Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 31. Rest of South America Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 32. Asia Pacific Dermatophytosis Drugs, by Country USD Million (2017-2022)
  • Table 33. Asia Pacific Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 34. Asia Pacific Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 35. Asia Pacific Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 36. Asia Pacific Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 37. China Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 38. China Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 39. China Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 40. China Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 41. Japan Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 42. Japan Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 43. Japan Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 44. Japan Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 45. India Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 46. India Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 47. India Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 48. India Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 49. South Korea Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 50. South Korea Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 51. South Korea Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 52. South Korea Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 53. Taiwan Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 54. Taiwan Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 55. Taiwan Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 56. Taiwan Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 57. Australia Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 58. Australia Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 59. Australia Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 60. Australia Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 61. Rest of Asia-Pacific Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 62. Rest of Asia-Pacific Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 65. Europe Dermatophytosis Drugs, by Country USD Million (2017-2022)
  • Table 66. Europe Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 67. Europe Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 68. Europe Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 69. Europe Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 70. Germany Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 71. Germany Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 72. Germany Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 73. Germany Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 74. France Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 75. France Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 76. France Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 77. France Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 78. Italy Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 79. Italy Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 80. Italy Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 81. Italy Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 82. United Kingdom Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 83. United Kingdom Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 84. United Kingdom Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 85. United Kingdom Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 86. Netherlands Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 87. Netherlands Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 88. Netherlands Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 89. Netherlands Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 90. Rest of Europe Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 91. Rest of Europe Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 92. Rest of Europe Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 93. Rest of Europe Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 94. MEA Dermatophytosis Drugs, by Country USD Million (2017-2022)
  • Table 95. MEA Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 96. MEA Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 97. MEA Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 98. MEA Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 99. Middle East Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 100. Middle East Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 101. Middle East Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 102. Middle East Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 103. Africa Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 104. Africa Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 105. Africa Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 106. Africa Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 107. North America Dermatophytosis Drugs, by Country USD Million (2017-2022)
  • Table 108. North America Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 109. North America Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 110. North America Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 111. North America Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 112. United States Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 113. United States Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 114. United States Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 115. United States Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 116. Canada Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 117. Canada Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 118. Canada Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 119. Canada Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 120. Mexico Dermatophytosis Drugs, by Application USD Million (2017-2022)
  • Table 121. Mexico Dermatophytosis Drugs, by Route of Administration USD Million (2017-2022)
  • Table 122. Mexico Dermatophytosis Drugs, by Form USD Million (2017-2022)
  • Table 123. Mexico Dermatophytosis Drugs, by End-Use USD Million (2017-2022)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Dermatophytosis Drugs: by Application(USD Million)
  • Table 135. Dermatophytosis Drugs Superficial Antifungal Infections , by Region USD Million (2023-2028)
  • Table 136. Dermatophytosis Drugs Systemic Antifungal Infections , by Region USD Million (2023-2028)
  • Table 137. Dermatophytosis Drugs: by Route of Administration(USD Million)
  • Table 138. Dermatophytosis Drugs Oral , by Region USD Million (2023-2028)
  • Table 139. Dermatophytosis Drugs Topical , by Region USD Million (2023-2028)
  • Table 140. Dermatophytosis Drugs Parenteral , by Region USD Million (2023-2028)
  • Table 141. Dermatophytosis Drugs: by Form(USD Million)
  • Table 142. Dermatophytosis Drugs Powder , by Region USD Million (2023-2028)
  • Table 143. Dermatophytosis Drugs Ointments , by Region USD Million (2023-2028)
  • Table 144. Dermatophytosis Drugs Tablets , by Region USD Million (2023-2028)
  • Table 145. Dermatophytosis Drugs: by End-Use(USD Million)
  • Table 146. Dermatophytosis Drugs Adult , by Region USD Million (2023-2028)
  • Table 147. Dermatophytosis Drugs Kids , by Region USD Million (2023-2028)
  • Table 148. South America Dermatophytosis Drugs, by Country USD Million (2023-2028)
  • Table 149. South America Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 150. South America Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 151. South America Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 152. South America Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 153. Brazil Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 154. Brazil Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 155. Brazil Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 156. Brazil Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 157. Argentina Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 158. Argentina Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 159. Argentina Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 160. Argentina Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 161. Rest of South America Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 162. Rest of South America Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 163. Rest of South America Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 164. Rest of South America Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 165. Asia Pacific Dermatophytosis Drugs, by Country USD Million (2023-2028)
  • Table 166. Asia Pacific Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 167. Asia Pacific Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 168. Asia Pacific Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 169. Asia Pacific Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 170. China Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 171. China Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 172. China Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 173. China Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 174. Japan Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 175. Japan Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 176. Japan Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 177. Japan Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 178. India Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 179. India Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 180. India Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 181. India Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 182. South Korea Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 183. South Korea Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 184. South Korea Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 185. South Korea Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 186. Taiwan Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 187. Taiwan Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 188. Taiwan Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 189. Taiwan Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 190. Australia Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 191. Australia Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 192. Australia Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 193. Australia Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 194. Rest of Asia-Pacific Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 195. Rest of Asia-Pacific Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 196. Rest of Asia-Pacific Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 197. Rest of Asia-Pacific Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 198. Europe Dermatophytosis Drugs, by Country USD Million (2023-2028)
  • Table 199. Europe Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 200. Europe Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 201. Europe Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 202. Europe Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 203. Germany Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 204. Germany Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 205. Germany Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 206. Germany Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 207. France Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 208. France Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 209. France Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 210. France Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 211. Italy Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 212. Italy Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 213. Italy Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 214. Italy Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 215. United Kingdom Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 216. United Kingdom Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 217. United Kingdom Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 218. United Kingdom Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 219. Netherlands Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 220. Netherlands Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 221. Netherlands Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 222. Netherlands Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 223. Rest of Europe Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 224. Rest of Europe Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 225. Rest of Europe Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 226. Rest of Europe Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 227. MEA Dermatophytosis Drugs, by Country USD Million (2023-2028)
  • Table 228. MEA Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 229. MEA Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 230. MEA Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 231. MEA Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 232. Middle East Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 233. Middle East Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 234. Middle East Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 235. Middle East Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 236. Africa Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 237. Africa Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 238. Africa Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 239. Africa Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 240. North America Dermatophytosis Drugs, by Country USD Million (2023-2028)
  • Table 241. North America Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 242. North America Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 243. North America Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 244. North America Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 245. United States Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 246. United States Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 247. United States Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 248. United States Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 249. Canada Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 250. Canada Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 251. Canada Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 252. Canada Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 253. Mexico Dermatophytosis Drugs, by Application USD Million (2023-2028)
  • Table 254. Mexico Dermatophytosis Drugs, by Route of Administration USD Million (2023-2028)
  • Table 255. Mexico Dermatophytosis Drugs, by Form USD Million (2023-2028)
  • Table 256. Mexico Dermatophytosis Drugs, by End-Use USD Million (2023-2028)
  • Table 257. Research Programs/Design for This Report
  • Table 258. Key Data Information from Secondary Sources
  • Table 259. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dermatophytosis Drugs: by Application USD Million (2017-2022)
  • Figure 5. Global Dermatophytosis Drugs: by Route of Administration USD Million (2017-2022)
  • Figure 6. Global Dermatophytosis Drugs: by Form USD Million (2017-2022)
  • Figure 7. Global Dermatophytosis Drugs: by End-Use USD Million (2017-2022)
  • Figure 8. South America Dermatophytosis Drugs Share (%), by Country
  • Figure 9. Asia Pacific Dermatophytosis Drugs Share (%), by Country
  • Figure 10. Europe Dermatophytosis Drugs Share (%), by Country
  • Figure 11. MEA Dermatophytosis Drugs Share (%), by Country
  • Figure 12. North America Dermatophytosis Drugs Share (%), by Country
  • Figure 13. Global Dermatophytosis Drugs share by Players 2022 (%)
  • Figure 14. Global Dermatophytosis Drugs share by Players (Top 3) 2022(%)
  • Figure 15. Global Dermatophytosis Drugs share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 19. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 20. Astellas Pharma Inc. (Japan) Revenue: by Geography 2022
  • Figure 21. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 23. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2022
  • Figure 25. Glenmark Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 26. Glenmark Pharmaceuticals (India) Revenue: by Geography 2022
  • Figure 27. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck & Co. Inc. (United States) Revenue: by Geography 2022
  • Figure 29. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 31. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 33. SCYNEXIS Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. SCYNEXIS Inc. (United States) Revenue: by Geography 2022
  • Figure 35. Kramer Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 36. Kramer Laboratories (United States) Revenue: by Geography 2022
  • Figure 37. Global Dermatophytosis Drugs: by Application USD Million (2023-2028)
  • Figure 38. Global Dermatophytosis Drugs: by Route of Administration USD Million (2023-2028)
  • Figure 39. Global Dermatophytosis Drugs: by Form USD Million (2023-2028)
  • Figure 40. Global Dermatophytosis Drugs: by End-Use USD Million (2023-2028)
  • Figure 41. South America Dermatophytosis Drugs Share (%), by Country
  • Figure 42. Asia Pacific Dermatophytosis Drugs Share (%), by Country
  • Figure 43. Europe Dermatophytosis Drugs Share (%), by Country
  • Figure 44. MEA Dermatophytosis Drugs Share (%), by Country
  • Figure 45. North America Dermatophytosis Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Astellas Pharma Inc. (Japan)
  • Bayer AG (Germany)
  • GlaxoSmithKline PLC (United Kingdom)
  • Glenmark Pharmaceuticals (India)
  • Merck & Co. Inc. (United States)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • SCYNEXIS Inc. (United States)
  • Kramer Laboratories (United States)
Select User Access Type

Key Highlights of Report


Dec 2023 208 Pages 68 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dermatophytosis Drugs Market Quantitative research analysis
Global Dermatophytosis Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2028
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.

Know More About Global Dermatophytosis Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Pharmaceutical and Medicinal Herbal Extracts Comprehensive Study by Type (Capsule, Tablet, Powder, Others), Application (Treatment, Massage, Medicines), End-Use (Traditional Chinese Medicine, Western...
$ 3350
Clopidogrel Bisulfate Comprehensive Study by Application (Heart Attacks, Strokes, Peripheral Arterial Diseases), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacies, Ret...
$ 3350
Gemcitabine Comprehensive Study by Application (Pancreas Cancer, Non-Small Cell Lung Cancer, Bladder Cancer, Soft-Tissue Sarcoma, Metastatic Breast Cancer, Ovarian Cancer), Distribution Channel (Hosp...
$ 3450
Antiplatelet Drugs Comprehensive Study by Application (Myocardial Infraction, Percutaneous Coronary Interventions, Angioplasty, Arterial Thrombosis, Dental surgeries, Others), Drug Type (Aspirin, Clo...
$ 3650
Lufenuron Comprehensive Study by Application (Fungal Infections, Ringworm, Agricultural Pesticide, Others), End (Dog, Cat, Other) Players and Region - Global Market Outlook to 2030
$ 3500
Tazarotene Comprehensive Study by Application (Psoriasis, Acne, Sun Damaged Skin, Others), Form (Cream, Gel, Foam), Distribution Channel (Online, Offline), Concentrations (0.05%, 0.1%) Players and Re...
$ 3500